Moderna performed a miracle last year: The Cambridge biotech company, which hadn’t put a product on the market since it was founded in 2010, delivered a coronavirus vaccine in just 11 months.
Investors — including company executives — were richly rewarded. The stock soared by more than 700 percent from Jan. 22, when Moderna disclosed it was working with the government to develop a COVID-19 vaccine, through Dec. 8, when the price peaked and the company briefly surpassed Vertex Pharmaceuticals as the biggest biotech in Massachusetts, by market value.
